Amylyx Files Offering Same Day as Phase 3 Win
Amylyx Pharmaceuticals surged 45% after Avexitide posted positive Phase 3 results for post-bariatric hypoglycemia and congenital hyperinsulinism, conditions with no currently approved therapies, then
Amylyx Files Offering Into Avexitide Phase 3 Pop
NEW YORK, August 19 —
Amylyx Pharmaceuticals, Inc. (AMLX) delivered positive Phase 3 results for Avexitide on August 18 and filed a share offering the same evening, a sequence that reads less like a triumph than a capital raise timed to peak optimism. At $35.11, the stock already sits 25% above the analyst consensus target of $28.09.
- AMLX surged 45% after Avexitide's Phase 3 results; Amylyx filed a 424B5 prospectus supplement the same day.
- Operating cash burn of $127 million annually; $250 million cash on hand implies roughly two years of runway.
- CLO Gina Mazzariello sold 30,000 shares at $17.61, $18.32 in July, prices roughly half the post-trial $35.11.
What Avexitide Actually Proved
Avexitide is a first-in-class GLP-1 receptor antagonist that blocks GLP-1 to prevent post-bariatric hypoglycemia and congenital hyperinsulinism, two rare conditions with no currently approved therapies. That "rare" qualifier matters for a company now carrying a $3.91 billion market cap: orphan indications have pricing power but structural volume ceilings. The Phase 3 readout confirmed the mechanism works; Amylyx disclosed the results in an 8-K under Regulation FD. Amylyx, founded in 2013 and based in Cambridge with 136 employees, also has AMX0035 in Phase 2 for Wolfram syndrome and Phase 2b/3 for progressive supranuclear palsy, and AMX0114 in Phase 1 for ALS.
Selling Into the Pop
The timing of the 424B5 filing says everything about Amylyx's situation. The company burns $127 million in operating cash per year with no commercial revenue and $250 million on hand, roughly two years of runway at current burn. Filing a prospectus supplement the same day as the catalyst is textbook strategy: sell equity at the highest price the market has offered before due diligence sets in. At $35.11, the stock is 25% above analyst consensus. Last quarter's EPS of -$0.39 missed estimates by 8.4%, and a DCF model built on any approval timeline would struggle to validate the current price.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| AMLX | $3.9B | n/a | +349.0% |
| FDMT | $813M | n/a | +114.9% |
| TSHA | $2.0B | n/a | +115.7% |
| ARQT | $3.3B | 20.4x | +68.1% |
| STOK | $2.1B | n/a | +66.4% |
| EWTX | $4.8B | n/a | +218.7% |
Two Signals the Rally Ignores
The CLO's July sales deserve close reading. Gina Mazzariello sold 30,000 shares across two days: 15,000 at $18.32 on July 9 and another 15,000 at $17.61 on July 10, for combined proceeds of $538,868 per Form 4 filings. Those prices were roughly half the current post-trial level, meaning either the sales were routine or Mazzariello had no advance view of the catalyst. A 15.6% short interest heading into the readout confirms the skepticism was widespread, and Phase 3 success does not automatically convert it. The thesis turns bullish if the next quarterly cash balance shows the offering extended runway past FDA submission; it stays neutral until that number is known. Run the free Amylyx Pharmaceuticals, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What is Avexitide and what conditions does it treat?
Avexitide is a first-in-class GLP-1 receptor antagonist that works by blocking GLP-1. It targets post-bariatric hypoglycemia and congenital hyperinsulinism, two rare conditions with no currently approved therapies. The Phase 3 readout confirmed the science works, disclosed via an 8-K under Regulation FD.
Why did Amylyx file a share offering after Phase 3 results?
Amylyx burns approximately $127 million in operating cash per year with no commercial revenue and had $250 million on hand, implying roughly two years of runway at current burn. Filing a prospectus supplement on the same day as a major positive catalyst is textbook strategy: sell equity at the highest price the market has offered before due diligence sets in.
What did Amylyx's CLO sell before the Phase 3 readout?
level of $35.11.
How does Amylyx's stock compare to analyst targets?
At $35.11 following the Phase 3 announcement, Amylyx shares sit 25% above the analyst consensus price target of $28.09. Last quarter's EPS of -$0.39 missed estimates by 8.4%, and a 15.6% short interest heading into the readout confirmed that skepticism was widespread before the catalyst.
What other drugs does Amylyx have in its pipeline?
Beyond Avexitide, Amylyx has AMX0035 in Phase 2 for Wolfram syndrome and Phase 2b/3 for progressive supranuclear palsy. The company also has AMX0114 in Phase 1 for ALS.
Amylyx Pharmaceuticals announced positive Phase 3 results for its Avexitide GLP-1 blocker on August 18, sending shares up 45%. The company filed a 424B5 prospectus supplement to sell new shares the same day, with the stock now trading roughly 25% above the analyst consensus price target of $28.09.